Recognizing Progression and Fibrostenotic Disease in EoE

In ‘Recognizing Progression and Fibrostenotic Disease in EoE,’ our panel explores how misconceptions about who develops eosinophilic esophagitis can contribute to delayed diagnosis and how prolonged disease activity may influence structural progression. The experts challenge the traditional perception of EoE as primarily a disease of young White men, emphasizing that it can occur across ages, sexes, races, and ethnicities. Pediatric patients may also present differently from adults, making a broad clinical index of suspicion important.

The faculty then examine natural-history data linking longer diagnostic delays with greater prevalence of fibrostenotic disease. They discuss differences in pediatric and adult presentation and explain that increasing duration of untreated disease is associated with greater risk of rings, strictures, and narrowing. The panel defines fibrostenotic disease clinically and describes how these structural changes can impair swallowing and increase the risk for food impaction.

The conversation extends beyond delays before diagnosis to persistent inflammation after EoE has been recognized. Faculty emphasize that continued uncontrolled inflammation can promote scar formation and structural change, providing a rationale for active treatment and objective assessment rather than relying solely on symptoms. They also acknowledge that disease progression is heterogeneous and does not occur identically in every patient. Overall, the experts connect earlier diagnosis, inflammatory control, and individualized escalation with the broader goal of limiting long-term fibrostenotic complications.

Our next episode, ‘Individualizing Initial Treatment Selection in EoE,’ examines how clinicians choose among available therapies and determine when biologic treatment may be appropriate.